United Therapeutics Corporation (NASDAQ:UTHR) Given Average Rating of “Moderate Buy” by Brokerages

United Therapeutics Corporation (NASDAQ:UTHR) has been given a consensus rating of “Moderate Buy” by the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $619.4167.

Several research analysts have recently commented on UTHR shares. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday, May 7th. UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Raymond James Financial started coverage on United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st.

United Therapeutics Stock Performance

Shares of UTHR opened at $545.96 on Monday. The firm has a market cap of $23.18 billion, a price-to-earnings ratio of 20.15, a PEG ratio of 1.78 and a beta of 0.57. The stock has a 50 day moving average of $566.75 and a 200-day moving average of $521.65. United Therapeutics has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.63 EPS. On average, sell-side analysts predict that United Therapeutics will post 26.84 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total value of $5,185,385.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,113,210.79. The trade was a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $547.07, for a total value of $4,540,681.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $24,712,246.04. This represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 624,968 shares of company stock valued at $352,827,097 in the last quarter. Corporate insiders own 8.60% of the company’s stock.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares in the last quarter. Entrust Financial LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth $31,000. International Assets Investment Management LLC raised its stake in shares of United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after buying an additional 49 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.